Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue: +10.4%
EPS: −280.5%
Free cash flow: −60.4%
Total debt: +3.88%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

235.47 8.15 +3.59%

Follow JAZZ

Alert me

Market cap: $14.6B
P/E: 62.6×
Fwd P/E: 35.9×
Dividend yield: —
F-score: 5/9
Altman Z: 1.37
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Jazz Pharmaceuticals PLC (JAZZ) revenue by segment, product and region

	Q4 FY2017	Q3 FY2017	Q2 FY2017	Q1 FY2017	Q4 FY2016	Q3 FY2016	Q2 FY2016	Q1 FY2016
Xyrem	‡	‡	‡	‡	‡	‡	‡	‡
Erwinaze And Erwinase	‡	‡	‡	‡	‡	‡	‡	‡
Defitelio/defibrotide	‡	‡	‡	‡	‡	‡	‡	‡
Other	‡	‡	‡	‡	‡	‡	‡	‡
Vyxeos	‡	‡	‡	‡	‡	‡	‡	‡
Product And Services, Royalties And Contract Revenue	‡	‡	‡	‡	‡	‡	‡	‡
Sunosi	‡	‡	‡	‡	‡	‡	‡	‡
Prialt	‡	‡	‡	‡	‡	‡	‡	‡
Product sales, net	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Jazz Pharmaceuticals PLC (JAZZ) revenue by segment, product and region

Stockrow Weekly